Navigation Links
Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
Date:12/19/2007

ence and lasts a lifetime. Its best known symptoms are 'positive symptoms', which include hallucinations and delusions; but other mental functions are also affected, including social and motivational skills ('negative symptoms') and cognitive behaviors, like inattention and poor memory. Current antipsychotics are effective primarily on reducing positive symptoms but leave negative and cognitive symptoms untouched. Not only are current drugs incompletely active, but they also have limiting side effects, including troublesome actions on motor function, weight gain, and metabolic symptoms (diabetes and hyperlipidemia), along with sedation, constipation, dizziness, and loss of bladder control. Few people with schizophrenia regain normal psychosocial function; the medical need in this disease area is enormous.

CNSProfile(TM)

The Company has developed a state-of-the-art technology platform, called CNSProfile(TM) that is capable of generating a unique molecular signature for drug compounds. Specifically, CNSProfile(TM) measures the levels of phosphoproteins, proteins chemically linked at specific sites to phosphates. This profile provides the Company with a proprietary and unique window into the intracellular action of CNS drugs or drug candidates. Intra-Cellular Therapies uses this platform in its drug discovery and development efforts of proprietary compounds and also to evaluate in-licensing opportunities.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc. (ITI), is a biopharmaceutical company that is developing novel drugs for the treatment of diseases and disorders of the Central Nervous System (CNS). Building on the science generated from the Nobel Prize winning laboratory of Dr. Paul Greengard at The Rockefeller University, the Company develops compounds that have the potential to treat a wide range of diseases associated with the CNS, including schizophrenia, sleep disorders, Parkinson's and Alzheimer's disease, cognitive defi
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
2. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
3. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
4. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
5. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
6. Vital Therapies Announces Presentation of ELAD(R) Artificial Liver Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
7. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
10. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
11. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  Depomed, Inc. (NASDAQ: ... second quarter fiscal year 2014 financial results after the ... host a conference call beginning at 4:30 pm EDT, 1:30 ... access the call by dialing 877-317-6789 ( United ... will also be available via a live webcast on ...
(Date:7/25/2014)... LAS VEGAS , July 25, 2014 GrowBLOX ... of a binding Memorandum of Understanding ("MOU") with LaurelCo, LLC, ... to pursue the acquisition of both cultivation and dispensary medical ... . Pursuant to the MOU, GBLX will acquire a 20% ... use our proprietary GrowBLOX TM growing chambers, as well ...
(Date:7/25/2014)... ALBANY, New York , July 25, 2014 /PRNewswire/ ... published by Transparency Market Research "Global and China Insulin ... Insulin) - Industry Analysis, Size, Share, Growth, Trends and ... insulin market was valued at USD 19.99 billion in ... of 6.1% from 2013 to 2019 to reach USD ...
Breaking Medicine Technology:Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
... CVS Caremark Corporation (NYSE: CVS ) today announced that Tom Ryan , Chairman, President and CEO, ... to investors at the Barclays Capital 2010 Global Healthcare Conference on March 23, 2010 . The Company is ... ... , ...
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the fourth quarter and full year ended ... ... ... ...
Cached Medicine Technology:CVS Caremark to Present at the Barclays Capital 2010 Global Healthcare Conference 2CVS Caremark to Present at the Barclays Capital 2010 Global Healthcare Conference 3BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 5BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 6BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 7BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 8BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 9BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 10BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 11BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 12BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 13
(Date:7/25/2014)... Ticket Down is a reliable source for cheap ... at California Memorial Stadium. With the post-World Cup emotions still ... of the 2014 Guinness International Champions Cup have brought eight ... teams representing La Liga, English Premier League, Serie A, and ... football players from around the world to 12 American cities ...
(Date:7/25/2014)... 2014 On July 22, 2014, ... client and the nation’s number one provider of ... announced their partnership with TransAct Merchant Solutions’ National ... ISO/MSP of Chase Paymentech Solutions, LLC, which provides ... Companies that are members of TransAct’s National Association ...
(Date:7/25/2014)... Hastings and Hastings, a personal ... regard to personal injury claims, announces free initial consultations. ... legal services for those that have been injured as ... corporation. Free initial consultation services gives clients’ greater flexibility ... potential personal injury claim . It also offers clients ...
(Date:7/25/2014)... News) -- Shift workers, especially men, may be at higher ... such schedules, a new study suggests. Also at special ... schedule, with shifts moving around at various times of the ... one expert, Dr. Alan Manevitz, a clinical psychiatrist at Lenox ... known that working shifts disrupts many key body chemicals, creating ...
(Date:7/25/2014)... An experimental anti-inflammatory drug can protect vulnerable neurons ... of Parkinson,s disease, researchers at Emory University School ... published in the Journal of Parkinson,s Disease ... called XPro1595, can reach the brain at sufficient ... subcutaneous injection, like an insulin shot. Previous studies ...
Breaking Medicine News(10 mins):Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3Health News:Study Links Shift Work to Risk for Type 2 Diabetes 2Health News:Study Links Shift Work to Risk for Type 2 Diabetes 3Health News:Anti-inflammatory drug can prevent neuron loss in Parkinson's model 2
... Case Medical Center and Case Western Reserve University School ... beneficial for women in their 40s. According to a ... Journal of Roentgenology , women between ages 40 and ... earlier stages with smaller tumors than symptomatic women needing ...
... and the scientific community should work to ensure that ... supplements and cancer risk, according to a commentary published ... Cancer Institute . Evidence from animal, in vitro ... may lower cancer risk. However, the small number of ...
... care collaboration to diagnosis, treat and follow patients ... require rapid, resource-intensive care and confer a high ... 24 in Circulation . Specifically, cardiovascular emergencies, ... angina, out-of-hospital cardiac arrest (OHCA), acute aortic dissection ...
... make the difference between life and death for very low ... of Pennsylvania School of Nursing and released today in ... . In a comprehensive study of 72,235 infants born ... babies cared for in hospitals with the Magnet credential were ...
... -- For people with tinnitus, which features chronic ringing, ... poor sleep makes it even more difficult to cope ... study included 117 tinnitus patients treated at Henry Ford ... severe the patients, insomnia, the greater their complaints about ...
... feel too attached? Does one need to let go to mature? ... immature cells, neural stem cells must stick together in a protected ... make all of the cells that populate the nervous system. But ... must stop dividing, detach from their neighbors and migrate to where ...
Cached Medicine News:Health News:Study finds mammography beneficial for younger women 2Health News:Supplements and cancer prevention: A cautionary tale 2Health News:Is it time for regional cardiovascular emergency care systems across the US? 2Health News:Choosing the right hospital may save your baby's life 2Health News:Poor Sleep Heightens 'Ringing Ear' Disease Symptoms: Study 2Health News:Growing up as a neural stem cell: The importance of clinging together and then letting go 2Health News:Growing up as a neural stem cell: The importance of clinging together and then letting go 3
Stainless steel dull finish....
9 mm diameter pigtail curved blunt probes. Stainless steel. Round knurled handle with polished finish. Includes pre-cut polyethylene tubes. Overall length: 5.9 inches....
12 mm diameter pigtail curved probes with eyes 4mm back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.9 inches....
The Novus 2000 argon laser combines power, size, and versatility. Ideal for the office, clinic and operating room environments, Novus 2000 is the world's most widely accepted ophthalmic laser....
Medicine Products: